# Onconetix, Inc. (ONCO) · Edgar & Edgarette company card

> Onconetix (ONCO) saw revenue fall 67.7% in FY2025 to $1 million, operating margin -2190% against a -3.8% median for pharmaceutical preparations, equity 63.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1782107 · fiscal year ended 2025-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/ONCO) · [JSON](https://www.pops4.com/boards/company/ONCO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $815,371 |
| Revenue growth, 1 year | -67.7% |
| Revenue growth per year | 273.1% |
| Operating margin | -2190.0% (prior year -2238.0%) |
| Net margin | -1721.0% |
| Operating cash flow | −$10M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $5M |
| Long-term debt | — |
| Total assets | $25M |
| Total equity | $16M |
| Equity ÷ assets | 63.2% |
| Return on equity | -89.0% |
| Dividend per share | $1.23 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: -20.98 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: 27.95 (above the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$9.7M in FY2025); operating loss: a margin of -2190.0% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $815K (FY2025). Experience: revenue down 67.7% on the year, up 273.1% a year over 2 years; operating margin -2190.0%, up from -2238.0%. Soundness: equity 63.2% of assets, return on equity -89.0%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $1.2M and $2.2M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -2190.0% against a -3.8% median; growth -67.7% against 13.7%.

Range logged 2026-10-08, receipt 51a421c884bc18d3, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-04-24 ([filing](https://www.sec.gov/Archives/edgar/data/1782107/000121390026047577/0001213900-26-047577-index.htm))

## Recent filings

- 10-Q · filed 2026-11-16 · [filing](https://www.sec.gov/Archives/edgar/data/1782107/000121390026120764/0001213900-26-120764-index.htm)
- 8-K · filed 2026-11-12 · 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1782107/000121390026118266/0001213900-26-118266-index.htm)
- 8-K · filed 2026-11-09 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1782107/000121390026117223/0001213900-26-117223-index.htm)
- 8-K · filed 2026-11-06 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1782107/000121390026116512/0001213900-26-116512-index.htm)
- 8-K · filed 2026-10-26 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1782107/000121390026112527/0001213900-26-112527-index.htm)
- 8-K · filed 2026-10-23 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1782107/000121390026111944/0001213900-26-111944-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001782107.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1782107

## Cite

POPS4, Edgar & Edgarette: Onconetix, Inc. (ONCO) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/ONCO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

